APVO
Aptevo Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APVO
Aptevo Therapeutics Inc.
A biotechnology company developing novel immunotherapies for cancer and autoimmune diseases
Biological Technology
Invalid Date
08/01/2016
NASDAQ Stock Exchange
37
12-31
Common stock
2401 4th Avenue, Suite 1050, Seattle, Washington 98121
--
Aptevo Therapeutics Inc., was incorporated in Delaware in February 2016. The company is a clinical-stage R&D biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two multifunctional platform technologies for the rational design of precision immunomodulatory drugs. The Company's main clinical candidates APVO436 and ALG.APV-527 and preclinical candidates APVO603 and APVO711 were developed using the ADAPTIR modular protein technology platform. The company's preclinical drug candidate APVO 442 was developed using the ADAPTIR-FLEX modular protein technology platform. The company's ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific and multispecific candidate antibodies that enhance the human immune system against cancer cells.
Company Financials
EPS
APVO has released its 2025 Q2 earnings. EPS was reported at -8.4, versus the expected -83.2, beating expectations. The chart below visualizes how APVO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
